The Study
Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer
This study is like trying to say a toy causes a room to be messy, but we don’t know if the toy was randomly placed or just happened to be there. We can’t say it caused the mess—we just see it’s there.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists found that a gene called RRAS2, when too active, can turn normal breast cells into cancer — but only if the woman has been pregnant.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 558 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this gene overexpression is linked to the most aggressive breast cancer type and worse survival, and it’s more common in women who recently had children.
- 2In mice, 100% of pregnant females with extra RRAS2 got breast cancer.
- 3In women, 68% of breast cancers had too much RRAS2, especially in young moms with triple-negative cancer.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Molecular Cancer
Year
2024
Authors
C. Cifuentes, Clara L. Oeste, Isabel Fernández-Pisonero, Alejandro M Hortal, C. García-Macías, Jeanne Hochart, R. Rubira, L. Horndler, Carlos Horndler, Xosé R. Bustelo, Balbino Alarcón
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.